Presenter(s): Debra Newman, PA-C, MPAS, MPH; Andrew Saxon, MD; Annie Potter, NP, CARN-AP

Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior

Cost: No fee

Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, social workers, clinical administrators and healthcare teams.

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, SW CE credit, and Interprofessional Continuing Education (IPCE) credit.

Webinar Description: Once your clinical site leadership has demonstrated an interest in exploring buprenorphine or other pharmacotherapies as a treatment option for opioid use disorder (OUD) patients, you must determine how to best assess organizational needs in a number of key areas including patient screening and identification, clinical capacity, patient monitoring and referral, community engagement, and more. How do you ensure the broader clinical workforce is properly trained and confident in their ability to treat patients using pharmacotherapies, and ensure OUD patients have access to a continuum of treatment and care services? This session will review clinic-wide implementation of new medications, and address ways to engage, identify and motivate site champions to work toward the implementation and integration of this clinical service.

Educational Objectives:

• Discuss the critical role of champions and how to strategically select champions and implementation team members
• Prepare a site needs/asset assessment to identify facilitators and barriers to MOUD implementation
• Review the training and certifications required for specific team members to implement MOUD
• Illustrate skills to assess program readiness to implement MOUD and motivate healthcare teams toward adopting this evidenced-based practice